LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Androgen Receptor Signaling Inhibitors in Nonmetastatic Castration-resistant Prostate Cancer and Risk of Cardiovascular Toxicity: All That Glitters Isn't Gold.

Photo from wikipedia

Androgen receptor signaling inhibitors have a metastasis-free survival benefit for men with nonmetastatic castration-resistant prostate cancer. The latest updates for the PROSPER, SPARTAN, and ARAMIS trials also demonstrate an overall… Click to show full abstract

Androgen receptor signaling inhibitors have a metastasis-free survival benefit for men with nonmetastatic castration-resistant prostate cancer. The latest updates for the PROSPER, SPARTAN, and ARAMIS trials also demonstrate an overall survival benefit. However, the cardiovascular toxicity associated with prolonged use of these agents should be taken into consideration before initiating therapy.

Keywords: signaling inhibitors; nonmetastatic castration; castration resistant; receptor signaling; androgen receptor; resistant prostate

Journal Title: European urology
Year Published: 2020

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.